Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2008 AND VI 26 AND IP 4
Results: 8
1
2
The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
- Published in:
- 2008
- By:
- Publication type:
- journal article
3
Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
- Published in:
- 2008
- By:
- Publication type:
- journal article
4
An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 4, p. 329, doi. 10.2165/00019053-200826040-00005
- By:
- Publication type:
- Article
5
Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 4, p. 311, doi. 10.2165/00019053-200826040-00004
- By:
- Publication type:
- Article
6
The Use of QALY Weights for QALY Calculations.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 4, p. 297, doi. 10.2165/00019053-200826040-00003
- By:
- Publication type:
- Article
7
Making a Case for Employing a Societal Perspective in the Evaluation of Medicaid Prescription Drug Interventions.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 4, p. 281, doi. 10.2165/00019053-200826040-00002
- By:
- Publication type:
- Article
8
An Overview of Methods and Applications to Value Informal Care in Economic Evaluations of Healthcare.
- Published in:
- PharmacoEconomics, 2008, v. 26, n. 4, p. 269, doi. 10.2165/00019053-200826040-00001
- By:
- Publication type:
- Article